Rating Change
BNP Paribas reiterated its Neutral rating on AbbVie Inc. (NYSE:ABBV) on August 11, 2026.
BNP Paribas reiterated its Neutral rating on AbbVie Inc. (NYSE:ABBV) on August 11, 2026.

At publication ·
AbbVie Inc. (NYSE:ABBV) · reiterate
At a glance
BNP Paribas reiterated its Neutral rating on AbbVie Inc. (NYSE:ABBV) on August 11, 2026.
AbbVie Inc. operates in the Healthcare sector. The stock currently trades at $249.94 with a market capitalization of $410.1B. The stock has gained 9.0% over the past 52 weeks.
Analyst coverage from BNP Paribas provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for AbbVie Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 11, 2026 | BNP Paribas | Neutral | N/A |
| Aug 10, 2026 | Evercore ISI Group | Outperform | N/A |
| Aug 04, 2026 | Guggenheim | Buy | N/A |
| Aug 03, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Aug 03, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ABBV Stock Page
A rating of Neutral from BNP Paribas reflects the analyst's outlook on AbbVie Inc. (NYSE:ABBV). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ABBV forecast page.
Current market data
NYSE · ABBV
$261.72
Up: +$1.71 · +0.66%
Live quote updated
Keep reading